

RESPIVAC aMPV (--)- Lyophilisate for ocular suspension/use in drinking water

Authorised

- Turkey rhinotracheitis virus, strain 1062, Live

Product identification

Medicine name:

RESPIVAC aMPV (--)- Lyophilisate for ocular suspension/use in drinking water

Active substance:

Turkey rhinotracheitis virus, strain 1062, Live

Target species:

Chicken

Route of administration:

Ocular use
In drinking water use

Product details

Active substance and strength:

Turkey rhinotracheitis virus, strain 1062, Live

Presentation_strength: $10^{1.8}$ - $10^{5.4}$ CCID₅₀/dose Reference: Ph. Eur. Index: 0

Pharmaceutical form:

Lyophilisate for ocular nasal suspension/use in drinking water

Withdrawal period by route of administration:**Ocular nasal use:**

-

Chicken

- Not applicable. 0 day
Zero day

In drinking water use:

-

Chicken

- Not applicable. 0 day
Zero day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI01AD01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:

Packaging:Vial (glass), Package_size:10 vials, Content:10000 doses

Packaging:Vial (glass), Package_size:10 vials, Content:2000 doses

Packaging:Vial (glass), Package_size:1 vial, Content:10000 doses

Packaging:Vial (glass), Package_size:10 vials, Content:5000 doses

Packaging:Vial (glass), Package_size:1 vial, Content:5000 doses

Packaging:Vial (glass), Package_size:1 vial, Content:2000 doses

Packaging:Vial (glass), Package_size:10 vials, Content:1000 doses

Packaging:Vial (glass), Package_size:1 vial, Content:1000 doses

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - known active substance (Article 8 of Regulation (EU) 2019/6)

Marketing authorisation holder:

Laboratorios Hipra, S.A.

Marketing authorisation date:

30/05/2024

Manufacturing sites for batch release:

Laboratorios Hipra S.A.

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

30/05/2024

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 21/10/2024

Download

ema-puar-v6160-respivacampv-former-respivactrt-en.pdf